ANNX Annexon, Inc.

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntingtonís and alzheimerís disease, multiple sclerosis, glaucoma, parkinsonís disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in South San Francisco, CA.

$16.30  +0.66 (4.22%)
As of 12/07/2021 13:28:16 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/24/2020
Outstanding shares:  38,374,846
Average volume:  269,323
Market cap:   $604,403,825
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    03589W102
ISIN:        US03589W1027
Sedol:      BMVV9R5
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.27
PS ratio:   0.00
Return on equity:   -43.89%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy